bpc-157 peptide Explained: Benefits, Safety & Oral vs Injectable Options BPC-157 - Injectable Peptide

Common Mild Reactions Local irritation where the peptide was injected (minor redness or tenderness) Occasional dizziness or fatigue shortly after use Typically mild and short-lived Potential Risks Not FDA-approved for Lyme disease or any other condition Contraindicated in active cancer due to its angiogenesis-promoting properties Should be avoided during pregnancy or breastfeeding Take Precautions with Medical Guidance Since its administered via injection and isnt regulated for Lyme treatment, a professional Lyme disease expert should guide your dosing

The injection is given in the upper arm or thigh muscle, allowing rapid absorption

What is your refund and cancellation policy

These platforms usually provide detailed instructions on how to administer the injections correctly